Possibility to use iPS-technology in age-related diseases

Author

Zhao Cheng ; Ito, Satoshi ; Nishio, Nobuhiko ; Suganya, T. ; Isobe, Keisuke

Author_Institution

Grad. Sch. of Med., Dept. of Immunology, Nagoya Univ., Nagoya, Japan

fYear

2012

fDate

4-7 Nov. 2012

Firstpage

116

Lastpage

120

Abstract

When applying the iPSCs for regenerative therapy in elderly patients, it is necessary to establish the iPSCs from elderly patients themselves then differentiate the iPSCs to specific cell types for transplantation treatments. The mouse is a perfect model to study aging in mammals. Bone marrow (BM) cells from aged C57BL/6 mice (15 months to 21 months) were cultured with granulocyte macrophage-colony stimulating factor (GM-CSF). The efficiency to produce iPSCs from aged mice BM cells was lower than that of young mice. We established several clones of iPSCs from aged mice. All the established clones have pluripotent markers. Aged-iPSCs could differentiate to three germ layers in vitro and made teratoma in vivo. We are currently making chimeric mice between Aged-iPSC-1 and ICR mice.

Keywords

bone; cellular biophysics; diseases; gene therapy; geriatrics; molecular biophysics; tissue engineering; C57BL-6 mice; GMCSF; ____________; age 1.25 yr to 1.75 yr; age related diseases; aged ICR mice; aged iPSC-1 mice; bone marrow cells; chimeric mice; clone pluripotent markers; elderly patients; granulocyte macrophage colony stimulating factor; iPS technology; iPSC clones; iPSC differentiation; in vitro germ layers; in vivo teratoma; mammal aging; mouse model; regenerative therapy; specific cell types; transplantation treatments;

fLanguage

English

Publisher

ieee

Conference_Titel

Micro-NanoMechatronics and Human Science (MHS), 2012 International Symposium on

Conference_Location

Nagoya

Print_ISBN

978-1-4673-4811-9

Type

conf

DOI

10.1109/MHS.2012.6492465

Filename

6492465